LXRX - Lexicon Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
Enterprise Value 3
Trailing P/E
Forward P/E 1
PEG Ratio (5 yr expected) 1
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue 3
Enterprise Value/EBITDA 6

Trading Information

Stock Price History

Beta (3Y Monthly) 1.53
52-Week Change 3-63.88%
S&P500 52-Week Change 36.64%
52 Week High 39.3300
52 Week Low 31.1300
50-Day Moving Average 32.6791
200-Day Moving Average 34.4358

Share Statistics

Avg Vol (3 month) 32.55M
Avg Vol (10 day) 31.39M
Shares Outstanding 5106.27M
Float N/A
% Held by Insiders 10.40%
% Held by Institutions 1101.30%
Shares Short (Sep 30, 2019) 49.67M
Short Ratio (Sep 30, 2019) 42.48
Short % of Float (Sep 30, 2019) 436.82%
Short % of Shares Outstanding (Sep 30, 2019) 49.10%
Shares Short (prior month Aug 30, 2019) 48.03M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 27/1
Last Split Date 3May 21, 2015

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019


Profit Margin -207.28%
Operating Margin (ttm)-166.09%

Management Effectiveness

Return on Assets (ttm)-15.75%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)42.94M
Revenue Per Share (ttm)0.41
Quarterly Revenue Growth (yoy)-29.80%
Gross Profit (ttm)-39.52M
EBITDA -69.47M
Net Income Avi to Common (ttm)-88.99M
Diluted EPS (ttm)-0.8390
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)105.98M
Total Cash Per Share (mrq)1
Total Debt (mrq)246.95M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)5.45
Book Value Per Share (mrq)-0.61

Cash Flow Statement

Operating Cash Flow (ttm)-101.83M
Levered Free Cash Flow (ttm)-93.28M